Nina Bozinov, MD
Neurology · Coeur D Alene, IDNPI 1508286188
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by EMD Serono, Inc. at 55.4% of the total. Reporting peaked in 2023 at $40,633 and has fallen 60.9% since, to $15,905 in 2025. Among neurology clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 143 payments — averaging $533.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$42K
- Genentech USA, Inc.$20K
- Amgen$7K
- Biogen$3K
- Novartis$2K
- TG Therapeutics, Inc.$2K
- plus $850 from 12 others
Across 9 payments — averaging $48,049 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$428K
- TG Therapeutics, Inc.$4K
What the payments were for
- Consulting fees$45,07959%
- Speaking & faculty fees$21,27028%
- Travel & lodging$4,2296%
- Food & beverage$5,6117%
- Education$560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 42 | $42,236 |
| Genentech USA, Inc. | 24 | $19,968 |
| Amgen(2 entities) | 9 | $6,903 |
| Biogen | 12 | $2,935 |
| Novartis | 10 | $1,680 |
| TG Therapeutics, Inc. | 14 | $1,672 |
| AstraZeneca | 3 | $262 |
| Bristol Myers Squibb | 16 | $244 |
| E.r. Squibb & Sons, L.L.C. | 1 | $74 |
| AbbVie | 3 | $70 |
| Genentech, Inc. | 2 | $49 |
| Acadia Pharmaceuticals Inc | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| SK Life Science, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$76,244 in reported general payments places this provider in the 90th percentile of 59 neurology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 438 | $3,725,289 |
| EnspryngSatralizumab-Mwge | 13 | $209,893 |
| GilenyaFingolimod Hcl | 14 | $162,259 |
| MayzentSiponimod | 16 | $148,610 |
| CopaxoneGlatiramer Acetate | 25 | $139,056 |
| Dimethyl Fumarate | 43 | $120,228 |
| ZeposiaOzanimod Hydrochloride | 12 | $107,221 |
| TysabriNatalizumab | 13 | $95,514 |
| MyrbetriqMirabegron | 68 | $48,952 |
| Glatiramer Acetate | 35 | $48,761 |
| Dalfampridine ErDalfampridine | 100 | $42,680 |
| GemtesaVibegron | 61 | $30,754 |
| Nurtec OdtRimegepant Sulfate | 17 | $29,040 |
| NuedextaDextromethorphan Hbr/Quinidine | 17 | $25,724 |
| Emgality PenGalcanezumab-Gnlm | 31 | $24,097 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisGilenya, Mayzent | $1,680 | $310,86930 claims |
| Genentech USA, Inc.Enspryng | $19,968 | $209,89313 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $74 | $107,22112 claims |
| BiogenTysabri | $2,935 | $95,51413 claims |
| AbbVieQulipta, Linzess | $70 | $25,67130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 59 neurology providers in Idaho.
Other neurology in Coeur D Alene
- Angela PanaCoeur D Alene$37K
- Cliff HamptonCoeur D Alene$1K
- Lizl LaskyCoeur D Alene$1K
- Charles BrittCoeur D Alene$909
- David SchreiberCoeur D Alene$166
- Michah BrasseurCoeur D Alene$146
- Matthew WomeldorffCoeur D Alene$70
- Bradford TalcottIdaho Falls$252K
- Lawrence GreenNampa$193K
- Stephen VincentIdaho Falls$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.